NASDAQ: HEPAHepion Pharmaceuticals Inc Stock
$2.11-0.02 (-0.94%)
Updated Apr 18, 2024
HEPA Price
$2.11
Fair Value Price
$3.67
Market Cap
$11.56M
52 Week Low
$1.49
52 Week High
$20.66
P/E
-0.17x
P/B
1.59x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$48.93M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.49
Operating Cash Flow
-$41M
Beta
0.64
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
HEPA Overview
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HEPA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HEPA ($2.11) is undervalued by 42.47% relative to our estimate of its Fair Value price of $3.67 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
HEPA ($2.11) is significantly undervalued by 42.47% relative to our estimate of its Fair Value price of $3.67 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
HEPA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HEPA due diligence checks available for Premium users.
Be the first to know about important HEPA news, forecast changes, insider trades & much more!
HEPA News
Valuation
HEPA fair value
Fair Value of HEPA stock based on Discounted Cash Flow (DCF)
Price
$2.11
Fair Value
$3.67
Undervalued by
42.52%
HEPA ($2.11) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HEPA ($2.11) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HEPA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HEPA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.17x
Industry
15.68x
Market
41.33x
HEPA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.59x
Industry
5.76x
HEPA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HEPA's financial health
Profit margin
Revenue
$0.0
Net Income
-$11.1M
Profit Margin
0%
HEPA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$18.1M
Liabilities
$10.8M
Debt to equity
1.49
HEPA's short-term assets ($17.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HEPA's short-term assets ($17.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HEPA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HEPA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.0M
Investing
-$348.0
Financing
$4.5M
HEPA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HEPA vs Biotech Stocks
Hepion Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.